142 related articles for article (PubMed ID: 24336193)
1. The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome.
Avery-Kiejda KA; Morten B; Wong-Brown MW; Mathe A; Scott RJ
Carcinogenesis; 2014 Mar; 35(3):586-96. PubMed ID: 24336193
[TBL] [Abstract][Full Text] [Related]
2. p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients.
Bourdon JC; Khoury MP; Diot A; Baker L; Fernandes K; Aoubala M; Quinlan P; Purdie CA; Jordan LB; Prats AC; Lane DP; Thompson AM
Breast Cancer Res; 2011 Jan; 13(1):R7. PubMed ID: 21251329
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the QuantiGene 2.0 Assay and Real-Time RT-PCR in the Detection of p53 Isoform mRNA Expression in Formalin-Fixed Paraffin-Embedded Tissues- A Preliminary Study.
Morten BC; Scott RJ; Avery-Kiejda KA
PLoS One; 2016; 11(11):e0165930. PubMed ID: 27832134
[TBL] [Abstract][Full Text] [Related]
4. Expression of p53 isoforms in renal cell carcinoma.
Song W; Huo SW; Lü JJ; Liu Z; Fang XL; Jin XB; Yuan MZ
Chin Med J (Engl); 2009 Apr; 122(8):921-6. PubMed ID: 19493415
[TBL] [Abstract][Full Text] [Related]
5. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
[TBL] [Abstract][Full Text] [Related]
6. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
[TBL] [Abstract][Full Text] [Related]
7. High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma.
Bischof K; Knappskog S; Stefansson I; McCormack EM; Trovik J; Werner HMJ; Woie K; Gjertsen BT; Bjorge L
BMC Cancer; 2018 Jun; 18(1):684. PubMed ID: 29940909
[TBL] [Abstract][Full Text] [Related]
8. Expression of p53 N-terminal isoforms in B-cell precursor acute lymphoblastic leukemia and its correlation with clinicopathological profiles.
Oh L; Hainaut P; Blanchet S; Ariffin H
BMC Cancer; 2020 Feb; 20(1):110. PubMed ID: 32041553
[TBL] [Abstract][Full Text] [Related]
9. Cytoplasmic p53β Isoforms Are Associated with Worse Disease-Free Survival in Breast Cancer.
Steffens Reinhardt L; Groen K; Morten BC; Bourdon JC; Avery-Kiejda KA
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743117
[No Abstract] [Full Text] [Related]
10. Role of p53β in the inhibition of proliferation of gastric cancer cells expressing wild-type or mutated p53.
Ji W; Ma J; Zhang H; Zhong H; Li L; Ding N; Jiao J; Gao Z
Mol Med Rep; 2015 Jul; 12(1):691-5. PubMed ID: 25695150
[TBL] [Abstract][Full Text] [Related]
11. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin.
Avery-Kiejda KA; Zhang XD; Adams LJ; Scott RJ; Vojtesek B; Lane DP; Hersey P
Clin Cancer Res; 2008 Mar; 14(6):1659-68. PubMed ID: 18310316
[TBL] [Abstract][Full Text] [Related]
12. Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.
Lenos K; Grawenda AM; Lodder K; Kuijjer ML; Teunisse AF; Repapi E; Grochola LF; Bartel F; Hogendoorn PC; Wuerl P; Taubert H; Cleton-Jansen AM; Bond GL; Jochemsen AG
Cancer Res; 2012 Aug; 72(16):4074-84. PubMed ID: 22700878
[TBL] [Abstract][Full Text] [Related]
13. The N-terminally truncated p53 isoform Δ40p53 influences prognosis in mucinous ovarian cancer.
Hofstetter G; Berger A; Berger R; Zorić A; Braicu EI; Reimer D; Fiegl H; Marth C; Zeimet AG; Ulmer H; Moll U; Zeillinger R; Concin N
Int J Gynecol Cancer; 2012 Mar; 22(3):372-9. PubMed ID: 22246403
[TBL] [Abstract][Full Text] [Related]
14. p53 isoforms can regulate p53 transcriptional activity.
Bourdon JC; Fernandes K; Murray-Zmijewski F; Liu G; Diot A; Xirodimas DP; Saville MK; Lane DP
Genes Dev; 2005 Sep; 19(18):2122-37. PubMed ID: 16131611
[TBL] [Abstract][Full Text] [Related]
15. Maintenance of p53 alterations throughout breast cancer progression.
Davidoff AM; Kerns BJ; Iglehart JD; Marks JR
Cancer Res; 1991 May; 51(10):2605-10. PubMed ID: 1850660
[TBL] [Abstract][Full Text] [Related]
16. Concomitant inactivation of p53 and Chk2 in breast cancer.
Sullivan A; Yuille M; Repellin C; Reddy A; Reelfs O; Bell A; Dunne B; Gusterson BA; Osin P; Farrell PJ; Yulug I; Evans A; Ozcelik T; Gasco M; Crook T
Oncogene; 2002 Feb; 21(9):1316-24. PubMed ID: 11857075
[TBL] [Abstract][Full Text] [Related]
17. Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation.
Zhao C; Lam EW; Sunters A; Enmark E; De Bella MT; Coombes RC; Gustafsson JA; Dahlman-Wright K
Oncogene; 2003 Oct; 22(48):7600-6. PubMed ID: 14576822
[TBL] [Abstract][Full Text] [Related]
18. Effect of p53 and its N-terminally truncated isoform, Δ40p53, on breast cancer migration and invasion.
Zhang X; Groen K; Morten BC; Steffens Reinhardt L; Campbell HG; Braithwaite AW; Bourdon JC; Avery-Kiejda KA
Mol Oncol; 2022 Jan; 16(2):447-465. PubMed ID: 34657382
[TBL] [Abstract][Full Text] [Related]
19. The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer.
Al Sarakbi W; Mokbel R; Salhab M; Jiang WG; Reed MJ; Mokbel K
Anticancer Res; 2006; 26(6C):4985-90. PubMed ID: 17214375
[TBL] [Abstract][Full Text] [Related]
20. Distinct promoter usage of mdm2 gene in human breast cancer.
Okumura N; Saji S; Eguchi H; Nakashima S; Saji S; Hayashi S
Oncol Rep; 2002; 9(3):557-63. PubMed ID: 11956627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
